4.6 Article

Chondroitin Sulfate Glycosaminoglycan Matrices Promote Neural Stem Cell Maintenance and Neuroprotection Post-Traumatic Brain Injury

Journal

ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 3, Issue 3, Pages 420-430

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.6b00805

Keywords

traumatic brain injury; biomaterials; neuroprotection; chondroitin sulfate glycosaminoglycan; neural stem cells; hydrogels

Funding

  1. University of Georgia CAES and OVPR
  2. Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center
  3. University of Georgia
  4. National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR00454]
  5. National Institutes of Health (NIH/NCRR) - entitled 'Integrated Technology Resource for Biomedical Glycomics' [1P41RR018502-01]

Ask authors/readers for more resources

There are currently no effective treatments for moderate-to-severe traumatic brain injuries (TBIs). The paracrine functions of undifferentiated neural stem cells (NSCs) are believed to play a significant role in stimulating the repair and regeneration of injured brain tissue. We therefore hypothesized that fibroblast growth factor (FGF2) enriching chondroitin sulfate glycosaminoglycan (CS-GAG) matrices can maintain the undifferentiated state of neural stem cells (NSCs) and facilitate brain tissue repair subacutely post-TBI. Rats subjected to a controlled cortical impactor (CCI) induced TBI were intraparenchymally injected with CS-GAG matrices alone or with CS-GAG matrices containing PKH26GL labeled allogeneic NSCs. Nissl staining of brain tissue 4 weeks post-TBI demonstrated the significantly enhanced (p < 0.05) tissue protection in CS-GAG treated animals when compared to TBI only control, and NSC only treated animals. CS-GAG-NSC treated animals demonstrated significantly enhanced (p < 0.05) FGF2 retention, and maintenance of PKH26GL labeled NSCs as indicated by enhanced Soxl+ and Ki67+ cell presence over other differentiated cell types. Lastly, all treatment groups and sham controls exhibited a significantly (p < 0.05) attenuated GFAP+ reactive astrocyte presence in the lesion site when compared to TBI only controls.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available